Rezolute (NASDAQ:RZLT) Given Buy Rating at HC Wainwright

Rezolute (NASDAQ:RZLT - Get Free Report)'s stock had its "buy" rating reaffirmed by stock analysts at HC Wainwright in a note issued to investors on Monday,Benzinga reports. They presently have a $14.00 price objective on the stock. HC Wainwright's price objective points to a potential upside of 279.92% from the company's current price.

RZLT has been the topic of a number of other research reports. Craig Hallum upgraded shares of Rezolute to a "strong-buy" rating in a report on Tuesday, February 4th. JMP Securities increased their target price on Rezolute from $8.00 to $9.00 and gave the company a "market outperform" rating in a research note on Thursday, February 13th. Finally, Guggenheim reissued a "buy" rating on shares of Rezolute in a research report on Monday, February 10th. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $26.43.

Rezolute Stock Down 4.3 %

RZLT traded down $0.17 on Monday, hitting $3.69. 426,986 shares of the company traded hands, compared to its average volume of 591,711. The company has a 50 day moving average of $3.36 and a 200-day moving average of $4.44. Rezolute has a 12-month low of $2.22 and a 12-month high of $6.19. The stock has a market capitalization of $223.07 million, a PE ratio of -3.01 and a beta of 0.97.

Rezolute (NASDAQ:RZLT - Get Free Report) last issued its quarterly earnings results on Wednesday, February 12th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.33) by $0.11. On average, research analysts anticipate that Rezolute will post -0.93 EPS for the current year.

Insider Buying and Selling at Rezolute

In other Rezolute news, CEO Nevan C. Elam bought 12,302 shares of the business's stock in a transaction on Thursday, March 27th. The shares were purchased at an average price of $2.85 per share, with a total value of $35,060.70. Following the completion of the acquisition, the chief executive officer now directly owns 224,119 shares of the company's stock, valued at approximately $638,739.15. The trade was a 5.81 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Wladimir Hogenhuis bought 10,000 shares of the firm's stock in a transaction on Tuesday, February 18th. The stock was bought at an average price of $4.70 per share, with a total value of $47,000.00. Following the completion of the purchase, the director now owns 77,267 shares of the company's stock, valued at $363,154.90. This trade represents a 14.87 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased 39,060 shares of company stock worth $130,694 in the last ninety days. 18.39% of the stock is owned by insiders.

Institutional Trading of Rezolute

Hedge funds have recently made changes to their positions in the stock. Jeppson Wealth Management LLC acquired a new stake in Rezolute in the first quarter worth $35,000. JPMorgan Chase & Co. bought a new stake in Rezolute in the 3rd quarter valued at about $42,000. Alpine Global Management LLC acquired a new position in Rezolute during the 4th quarter valued at about $54,000. Point72 Asia Singapore Pte. Ltd. boosted its stake in Rezolute by 48.5% during the 4th quarter. Point72 Asia Singapore Pte. Ltd. now owns 19,799 shares of the company's stock valued at $97,000 after purchasing an additional 6,470 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its position in Rezolute by 65.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 22,757 shares of the company's stock worth $112,000 after purchasing an additional 9,000 shares during the last quarter. Institutional investors own 82.97% of the company's stock.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.